A Phase 2 interventional study of IMG-007 in Atopic Dermatitis, Atopic Dermatitis Eczema and Eczema, sponsored by Inmagene LLC. Enrolling by invitation at 23 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by Inmagene LLC · Phase 2, Interventional, and Treatment
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)
1,591 studies on the registry are indexed under Dermatitis, Atopic; 286 are open to participants now.
This study's planned enrollment of 400 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →Inmagene LLC is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Enrolling by invitation participants with moderate to severe AD who have completed IMG-007-203
Subcutaneous injection as per protocol.
Drug: IMG-007
Participants will receive IMG-007 subcutaneously.
Evaluate the safety of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis
Incidence and severity of TEAEs, including treatment-emergent SAEs, AESIs, and AEs leading to discontinuation
Time frame: Baseline, Week 44
Characterize the safety of long-term treatment with IMG-007 based on body temperature (Celsius)
Time frame: Baseline, Week 44
Characterize the safety of long-term treatment with IMG-007 based on pulse rate (beats per minute)
Time frame: Baseline, Week 44
Characterize the safety of long-term treatment with IMG-007 based on respiratory rate (breaths per minute)
Time frame: Baseline, Week 44
Characterize the safety of long-term treatment with IMG-007 based on blood pressure (systolic and diastolic) (mmHg)
Time frame: Baseline, Week 44
Number of Participants With Clinically Significant Abnormal (defined by rate, rhythm, morphology, and conduction abnormalities) ECG Findings (unit is number of participants).
Time frame: Baseline, Week 44
Characterize the safety of long-term treatment with IMG-007, as assessed by hematology
Time frame: Baseline, Week 44
Characterize the safety of long-term treatment with IMG-007, as assessed by blood chemistry
Time frame: Baseline, Week 44
Characterize the safety of long-term treatment with IMG-007, as assessed by urinalysis
Time frame: Baseline, Week 44
Evaluate the effect of long-term treatment with IMG-007 on disease activity as assessed by Eczema Area and Severity Index (EASI)
Time frame: Baseline, Week 44
Evaluate the effect of long-term treatment with IMG-007 on disease activity as assessed by Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD)
Time frame: Baseline, Week 44
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IMG-007
Inmagene LLC